↓ Skip to main content
What is this page? Embed badge

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia

Overview of attention for article published in Cost Effectiveness and Resource Allocation, October 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

blogs
1 blog
twitter
3 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
31 Mendeley
Summary Blogs X Dimensions citations
So far, Altmetric has seen 1 blog post.

This page is provided by Altmetric.